4 terminated. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 3 | 1 | Terminated 1 |
Follow 0.9% normal saline: new trials by email Literature Review of 0.9% normal saline trials Research Report on 0.9% normal saline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia hzVSF-v13, Placebo (Normal saline solution) - COVID-19 | Phase 2 | Terminated | ImmuneMed, Inc. | 1 | 2021-03-18 | 2024-02-15 |
| Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19) Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment - COVID-19 | Phase 2 | Terminated | Grifols Therapeutics LLC | 57 | 2021-01-29 | 2023-03-22 |
| Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure Dociparstat sodium, Placebo - Coronavirus Disease 2019 (COVID-19), Acute Lung Injury | Phase 2 / Phase 3 | Terminated | Jazz Pharmaceuticals | 27 | 2020-07-08 | 2022-08-30 |
| Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection GEN-003, Matrix-M2, 0.9% normal saline - Genital Herpes, HSV-2 Infection | Phase 2 | Terminated | Genocea Biosciences, Inc. | 33 | 2017-05-24 | 2019-02-19 |
COVID-19 (3) · Acute Lung Injury (1) · Herpes Genitalis (1) · Herpes Simplex (1)
Genocea Biosciences, Inc. (1) · Grifols Therapeutics LLC (1) · ImmuneMed, Inc. (1) · Jazz Pharmaceuticals (1)
United States (3) · Brazil (1) · Chile (1) · Colombia (1) · Mexico (1) · South Korea (1)